
EHA 2025 | What are the latest updates from the STARGLO trial of Glofit-GemOx vs R-GemOx in R/R DLBCL?
This educational resource is independently supported by Roche. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.
During the 30th European Hematology Association (EHA) Congress, the Lymphoma Hub was pleased to speak to Gareth Gregory, Monash University, Melbourne, AU. We asked about the latest updates from the STARGLO trial of glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) vs rituximab plus gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.